Yu-Gang Liu

List of Publications by Year
in descending order

37 papers	1,490 citations	304743 22 h-index	361022 35 g-index
39 all docs	39 docs citations	39 times ranked	2005 citing authors

#	Article	IF	Citations
1	Surface chemistry-mediated modulation of adsorbed albumin folding state specifies nanocarrier clearance by distinct macrophage subsets. Nature Communications, 2021, 12, 648.	12.8	64
2	Enhancing subcutaneous injection and target tissue accumulation of nanoparticles via co-administration with macropinocytosis inhibitory nanoparticles (MiNP). Nanoscale Horizons, 2021, 6, 393-400.	8.0	10
3	Pâ€Stacking Enhances Stability, Scalability of Formation, Control over Flexibility, and Circulation Time of Polymeric Filamentous Nanocarriers. Advanced NanoBiomed Research, 2021, 1, 2100063.	3.6	6
4	209.8: Subcutaneous Nanotherapy Repurposes the Immunosuppressive Mechanism of Rapamycin to Enhance Allogeneic Islet Graft Viability. Transplantation, 2021, 105, S17-S17.	1.0	0
5	Employment of targeted nanoparticles for imaging of cellular processes in cardiovascular disease. Current Opinion in Biotechnology, 2020, 66, 59-68.	6.6	11
6	Magnetic Nanostructure-Loaded Bicontinuous Nanospheres Support Multicargo Intracellular Delivery and Oxidation-Responsive Morphological Transitions. ACS Applied Materials & Interfaces, 2020, 12, 55584-55595.	8.0	15
7	An Injectable Hydrogel Platform for Sustained Delivery of Anti-inflammatory Nanocarriers and Induction of Regulatory T Cells in Atherosclerosis. Frontiers in Bioengineering and Biotechnology, 2020, 8, 542.	4.1	21
8	XCage: A Tricyclic Octacationic Receptor for Perylene Diimide with Picomolar Affinity in Water. Journal of the American Chemical Society, 2020, 142, 3165-3173.	13.7	54
9	Surface Engineered Polymersomes for Enhanced Modulation of Dendritic Cells During Cardiovascular Immunotherapy. Advanced Functional Materials, 2019, 29, 1904399.	14.9	47
10	Celastrol-loaded PEG-b-PPS nanocarriers as an anti-inflammatory treatment for atherosclerosis. Biomaterials Science, 2019, 7, 657-668.	5.4	66
11	Polymersomes scalably fabricated via flash nanoprecipitation are non-toxic in non-human primates and associate with leukocytes in the spleen and kidney following intravenous administration. Nano Research, 2018, 11, 5689-5703.	10.4	43
12	Facile assembly and loading of theranostic polymersomes via multi-impingement flash nanoprecipitation. Journal of Controlled Release, 2017, 262, 91-103.	9.9	93
13	Immunotheranostic Polymersomes Modularly Assembled from Tetrablock and Diblock Copolymers with Oxidation-Responsive Fluorescence. Cellular and Molecular Bioengineering, 2017, 10, 357-370.	2.1	21
14	Tailoring Nanostructure Morphology for Enhanced Targeting of Dendritic Cells in Atherosclerosis. ACS Nano, 2016, 10, 11290-11303.	14.6	94
15	Engineering Nanomaterials to Address Cell-Mediated Inflammation in Atherosclerosis. Regenerative Engineering and Translational Medicine, 2016, 2, 37-50.	2.9	39
16	Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. Oncotarget, 2015, 6, 38983-38998.	1.8	38
17	MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Oncology Letters, 2015, 10, 3095-3102.	1.8	23
18	Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma. Cancer, 2014, 120, 3165-3177.	4.1	71

#	Article	IF	Citations
19	Anti-miR182 Reduces Ovarian Cancer Burden, Invasion, and Metastasis: An In Vivo Study in Orthotopic Xenografts of Nude Mice. Molecular Cancer Therapeutics, 2014, 13, 1729-1739.	4.1	55
20	Mitogen-activated protein kinase pathway is pivotal for anoikis resistance in metastatic hepatoma cells. Molecular Medicine Reports, 2014, 9, 1121-1127.	2.4	10
21	B- and T-Lymphocyte Attenuator/Herpes Virus Entry Mediator as Early Indicators for Acute Rejection Following Kidney Transplantation. Transplantation Proceedings, 2013, 45, 157-162.	0.6	4
22	miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2011, 411, 586-592.	2.1	134
23	Roles of TIPE2 in hepatitis B virus-induced hepatic inflammation in humans and mice. Molecular Immunology, 2011, 48, 1203-1208.	2.2	82
24	miR-122 inhibits viral replication and cell proliferation in hepatitis B virus-related hepatocellular carcinoma and targets NDRG3. Oncology Reports, 2011, 26, 1281-6.	2.6	85
25	Blocking TRAIL-DR5 signaling with soluble DR5 reduces delayed neuronal damage after transient global cerebral ischemia. Neurobiology of Disease, 2010, 39, 138-147.	4.4	37
26	Involvement of anoikis-resistance in the metastasis of hepatoma cells. Experimental Cell Research, 2009, 315, 1148-1156.	2.6	25
27	Up-regulation of Tropomyosin related kinase B contributes to resistance to detachment-induced apoptosis in hepatoma multicellular aggregations. Molecular Biology Reports, 2009, 36, 1211-1216.	2.3	15
28	Hepatitis B virus core protein inhibits TRAIL-induced apoptosis of hepatocytes by blocking DR5 expression. Cell Death and Differentiation, 2009, 16, 219-229.	11.2	78
29	Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through downregulating CD59. Molecular Immunology, 2009, 47, 283-289.	2.2	16
30	Acquisition of anoikis resistance reveals a synoikis-like survival style in BEL7402 hepatoma cells. Cancer Letters, 2008, 267, 106-115.	7.2	37
31	Blockade of preS2 down-regulates the apoptosis of HepG2.2.15 cells induced by TRAIL. Biochemical and Biophysical Research Communications, 2008, 369, 456-463.	2.1	8
32	Aggregation formation mediated anoikis resistance of BEL7402 hepatoma cells.. Folia Histochemica Et Cytobiologica, 2008, 46, 331-6.	1.5	10
33	Different effects of HBV and its viral proteins on TRAILâ€induced apoptosis and their distinct mechanisms. FASEB Journal, 2008, 22, 856.8.	0.5	0
34	Hepatitis B Virus Sensitizes Hepatocytes to TRAIL-Induced Apoptosis through Bax. Journal of Immunology, 2007, 178, 503-510.	0.8	100
35	Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. Biochemical and Biophysical Research Communications, 2007, 352, 329-334.	2.1	36
36	The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 1827-1836.	4.9	27

#	Article	IF	Citations
37	Establishment of mice model with human viral hepatitis B. World Journal of Gastroenterology, 2004, 10, 841.	3.3	14